Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Immunovia Interim Report, January-March 2019 | ||||||||||||||||||||||||||||||||||||||||||||
By: PR Newswire Association LLC. - 24 Apr 2019 | Back to overview list |
|||||||||||||||||||||||||||||||||||||||||||
STOCKHOLM, April 24, 2019 /PRNewswire/ -- During the first quarter of 2019, we remained focused on our product launch strategy and continued to create value, as we reached several key objectives and took several steps towards the commercialization of IMMray™ PanCan-d, our diagnostic test for early detection of pancreatic cancer. Another key objective that we reached in the first quarter was the addition of new participants to our PanFAM-1 study, a multicenter prospective validation study for early diagnosis of people with a high risk of hereditary pancreatic cancer. In Q1 2019 we added two additional centers, one in Sweden and one in Spain. Umeå University Hospital in Sweden and Catalan Institute of Oncology (ICO Hospitalet) – Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona are now part of PanFAM-1 study. We also took an extremely important step towards on the optimization of the algorithm during Q1. We announced in March that using blood samples that are as fresh as possible, i.e. stored for less than 24 months, increases the test performance and provides optimal results. We were able to attain the relevant samples through our large and growing network of clinical Key Opinion Leaders (KOL). It is imperative to note that we needed samples that best mirror the blood samples that will be used with our final product, finding these fresh samples and gaining access to them is quite difficult and takes time. With the appointment of Julie Silber as Senior Investor Relations Director early this year we actualized a strategic objective in strengthening the IR role and our shareholder communication capabilities at Immunovia. We continued to work intensely during the first quarter of 2019 on the preparations for our sales launch targeted for the beginning of 2020. Excerpt from the CEO Mats Grahn's comment on the report. Key Indicators
This financial statement has been produced in accordance with IFRS for the Immunovia Group, which comprises Immunovia AB and the wholly-owned subsidiaries Immunovia Incentive AB, Immunovia Inc. and Immunovia GmbH. Outlook The Company reiterates it's financial targets in accordance with what has previously been disclosed. The company anticipates the first revenues from self pay sales in early 2020.The following financial targets have been established:
Immunovia invites to a teleconference (in English) for investors, analysts and media on Monday April 29, at 3:00 – 4:00 p.m. CET. Mats Grahn, CEO will present Immunovia and comment on the interim report for the period January-March 2019, give an update from the Annual General Meeting on April 26, followed by a Q&A session. Please call in a few minutes in advance. To attend, please dial-in at one of the numbers below: BE: +3226200547 For questions or interview bookings: There will be an MP3-file available at Immunovia's webpage under Investors/Financial Reports (http://immunovia.com/investors/financial-reports/) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended. For more information, please contact: About Immunovia This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above. Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com. This information was brought to you by Cision http://news.cision.com https://news.cision.com/immunovia-ab/r/immunovia-interim-report--january-march-2019,c2795278 The following files are available for download:
View original content:http://www.prnewswire.com/news-releases/immunovia-interim-report-january-march-2019-300837208.html SOURCE Immunovia AB |
||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||
Copyright 2019 PR Newswire Association LLC. | Back to overview list |